Skip to main content

Table 1 Baseline characteristics

From: Selenium supplementation in patients with peripartum cardiomyopathy: a proof-of-concept trial

Characteristic Selenium supplementation group (n = 46) Controls (n = 54) p value
Biomarkers
 Serum selenium, μg/L 49.8 ± 10.8 48.1 ± 10.6 0.435
 Serum GPX, U/L 326.0 ± 121.9 362.0 ± 144.6 0.323
 Serum GPX > 470 U/L 3 (6.5%) 7 (13.0%) 0.466
Demographic and clinical characteristics
 Age, years 29.6 ± 7.3 28.9 ± 8.2 0.664
 Age < 20 years 5 (10.9%) 11 (20.4%) 0.277
 Age ≥ 35 years 7 (15.2%) 11 (20.4%) 0.536
 Hausa/Fulani ethnicity 43 (93.5%) 45 (83.3%) 0.137
 Unemployment 32 (69.6%) 46 (85.2%) 0.089
 No formal education 14 (30.4%) 25 (46.3%) 0.150
 Multiparty 31 (67.4%) 37 (68.5%) 0.904
 History of pre-eclampsia 13 (28.3%) 10 (18.5%) 0.249
 History of twins 9 (19.6%) 10 (18.5%) 0.894
 History of stroke 3 (6.5%) 0 0.094
 Body mass index, kg/m2 19.8 ± 6.4 20.6 ± 4.8 0.466
 Underweight 17 (37.0%) 13 (24.1%) 0.161
 Obesity 1 (2.2%) 1 (1.9%) 1.000
NYHA class    0.105
 I 15 (32.6%) 10 (18.5%)  
 II 19 (41.3%) 26 (48.1%)  
 III 7 (15.2%) 12 (22.2%)  
 IV 4 (8.7%) 5 (9.3%)  
Heart rate/min 96 ± 17 101 ± 27 0.055
Systolic BP, mmHg 108 ± 17 111 ± 17 0.291
Diastolic BP, mmHg 74 ± 12 77 ± 14 0.203
Hypertension 3 (6.5%) 6 (11.1%) 0.727
Hypotension 19 (41.3%) 20 (37.0%) 0.818
Heart failure treatments
 Loop diuretics 39 (84.8%) 45 (83.3%) 0.804
 ACEI or ARB 11 (23.9%) 15 (27.8%) 0.661
 Beta-blockers 9 (19.6%) 5 (9.3%) 0.139
 Spironolactone 42 (91.3%) 48 (88.9%) 0.750
 Digoxin 33 (71.7%) 36 (66.7%) 0.559
 Serum creatinine, μmol/L 73.9 ± 34.2 62.7 ± 48.4 0.210
 Plasma hemoglobin, g/dl 11.8 ± 3.4 11.3 ± 1.5 0.409
 Atrial fibrillation 0 1 (1.9%) 1.000
Echocardiography
 LA dimension, mm 45.1 ± 6.5 45.7 ± 5.8 0.609
 LVEDD, mm 62.1 ± 7.2 64.0 ± 7.8 0.212
 LVEF, % 30.9 ± 7.1 28.8 ± 8.0 0.186
 RV basal diameter, mm 42.7 ± 7.9 42.0 ± 6.9 0.655
 TAPSE, mm 14.1 ± 3.7 14.3 ± 2.7 0.756
 PASP, mmHg 42.8 ± 19.0 44.0 ± 18.2 0.764
 Intracardiac thrombus 2 (4.3%) 2 (3.7%) 0.416
  1. n, number of patients; GPX, glutathione peroxidase; NYHA, New York Heart Association; BP, blood pressure; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin II receptor blockers; LA, left atrium; LVEDD, left ventricular end-diastolic dimension; LVEF, LV ejection fraction; RV, right ventricle; TAPSE, tricuspid annular plane systolic excursion; PASP, pulmonary artery systolic pressure; *, p value statistically significant. All values were expressed as mean ± standard deviation, or as proportions